Frailty Predicts Survival and Toxicity in Newly Diagnosed Multiple Myeloma Patients Ineligible for Autologous Stem Cell Transplantation; Report of the HOVON-87/Nmsg-18 Study Group

Autor: Stege, C A M, Van Der Holt, B, Mellqvist, U H, Levin, M D, Salomo, M, Abildgaard, N, Bos, G, Visser-Wisselaar, H, Hansson, M, Van Der Velden, A, Deenik, W, Gruber, A, Coenen, J L L M, Plesner, T, Klein, S, Tanis, B, Szatkowski, D L, Brouwer, R, Westerman, M, Leijs, M B, Sinnige, H, Haukaas, E, Van Der Hem, K, Durian, M, Mattijssen, V, Gimsing, P, Van De Donk, N W C J, Stevens-Kroef, M, Sonneveld, P, Waage, A, Zweegman, S

Publikováno v: Stege, C A M, van der Holt, B, Mellqvist, U-H, Levin, M-D, Salomo, M, Abildgaard, N, Bos, G, Visser-Wisselaar, H, Hansson, M, van der Velden, A, Deenik, W, Gruber, A, Coenen, J L L M, Plesner, T, Klein, S, Tanis, B, Szatkowski, D L, Brouwer, R, Westerman, M, Leijs, M B, Sinnige, H, Haukås, E, van der Hem, K, Durian, M F, Mattijssen, V, Gimsing, P, Van De Donk, N WCJ, Stevens-Kroef, M, Sonneveld, P, Waage, A & Zweegman, S 2017, ' Frailty Predicts Survival and Toxicity in Newly Diagnosed Multiple Myeloma Patients Ineligible for Autologous Stem Cell Transplantation; Report of the HOVON-87/Nmsg-18 Study Group ', Blood, vol. 130, no. Suppl. 1, 3146 . < http://www.bloodjournal.org/content/130/Suppl_1/3146.full?sso-checked=true >
Stege, C A M, Van Der Holt, B, Mellqvist, U H, Levin, M D, Salomo, M, Abildgaard, N, Bos, G, Visser-Wisselaar, H, Hansson, M, Van Der Velden, A, Deenik, W, Gruber, A, Coenen, J L L M, Plesner, T, Klein, S, Tanis, B, Szatkowski, D L, Brouwer, R, Westerman, M, Leijs, M B, Sinnige, H, Haukaas, E, Van Der Hem, K, Durian, M, Mattijssen, V, Gimsing, P, Van De Donk, N W C J, Stevens-Kroef, M, Sonneveld, P, Waage, A & Zweegman, S 2017, Frailty predicts survival and toxicity in newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation; report of the HOVON-87/NMSG-18 study group . in Blood. Conference: 59th Annual Meeting of the American Society of Hematology, ASH . Blood. Conference: 59th Annual Meeting of the American Society of Hematology, ASH, vol. 130 . < http://www.bloodjournal.org/content/130/Suppl_1/3146 http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emexa&AN=620335289 >
Stege, C A M, Sonneveld, P, Plesner, T, Stevens-Kroef, M, van der Holt, B, Zweegman, S, Waage, A, Klein, S, Sinnige, H, Mellqvist, U-H, Abildgaard, N, Durian, M F, Hansson, M, Levin, M-D, Leijs, M B, Szatkowski, D L, Haukås, E, Salomo, M, Bos, G, Visser-Wisselaar, H, van der Velden, A, Deenik, W, Gruber, A, Coenen, J L L M, Tanis, B, Brouwer, R, Westerman, M, van der Hem, K, Mattijssen, V, Gimsing, P & Van De Donk, N WCJ 2017, ' Frailty Predicts Survival and Toxicity in Newly Diagnosed Multiple Myeloma Patients Ineligible for Autologous Stem Cell Transplantation; Report of the HOVON-87/Nmsg-18 Study Group ', 59th Annual Meeting and Exposition of the American Society of Hematology December 9-12th 2017, Atlanta, USA , Atlanta, United States, 09/12/2017-12/12/2017 .
Blood. Conference: 59th Annual Meeting of the American Society of Hematology, ASH

Introduction We previously reported the results of the phase III randomized HOVON-87/NMSG-18 study for Newly Diagnosed Multiple Myeloma patients not eligible for stem cell transplantation (nte-NDMM). The efficacy of melphalan, prednisolone and either

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::de954831a83b2ea33933ff13b8607d91
http://www.bloodjournal.org/content/130/Suppl_1/3146.full?sso-checked=true

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.